US equities |
SPCX $168.34 ▲+5.90% NVDA $237.26 ▲+1.41% MU $1,065.31 ▼-0.89% TSLA $378.41 ▲+2.11% MSFT $525.85 ▲+1.61% INTC $116.90 ▼-2.04% SNDK $1,721.63 ▲+0.10% META $745.10 ▲+2.34%
FinancialContent

Mural Oncology plc - Ordinary Shares (NQ:MURA)

2.040 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mural Oncology plc - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Nasdaq Gains 50 Points; US New Home Sales Rise In February ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
US Stocks Mixed; Core & Main Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges ↗
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Participate in Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Present at Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >